ASH announces new leadership
Click Here to Manage Email Alerts
ASH has named four new members to its executive committee beginning immediately after the 2024 ASH Annual Meeting.
Cynthia E. Dunbar, MD, chief of the translational stem cell biology branch within NHLBI’s intramural research program, will become vice president, followed by successive terms as president-elect and president, according to a press release.
Dunbar has made significant contributions in the field, specifically in hematopoiesis, bone marrow failure and gene therapies, according to the release.
She has served on various ASH committees for more than 3 decades, most recently serving as ASH secretary between 2021 and 2024. Dunbar became the first woman editor-in-chief of Blood, serving between 2007 to 2012.
“Hematology has seen enormous advances during my career, from basic and translational science to patient care,” Dunbar said in the release. “I look forward to working with [ASH] to strengthen the hematology workforce, promote access to existing and emerging therapies for patients with hematologic disorders, and improve research funding for hematology. I am honored to have the opportunity to serve the diverse hematology community.”
Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center in the division of hematologic malignancies at Dana-Farber Cancer Institute, and the Worthington and Margaret Collette professor of medicine in hematologic oncology at Harvard Medical School, will become ASH secretary.
Brown has been an ASH member since 2003 and is currently chair of the Committee on Educational Affairs, liaison to the Publications Committee and joint Program Committees. Her research has focused on targeted therapies for CLL and CLL genomics.
Chancellor Donald, MD, medical director of cancer management and oncology services at University Medical Center New Orleans (Tulane Division) and assistant professor of medicine at Tulane University School of Medicine, and Jennifer Holter-Chakrabarty, MD, professor of hematology/oncology at University of Oklahoma, have been named as councilors.
Donald has been an ASH member since 2008 where he has served as chair of the Committee on Practice, an appointed member of the Health Equity Task Force, and the ASH delegate to the American Medical Association House of Delegates. His academic focus includes advocacy and health disparities among patients with hematologic disorders and malignancies.
Holter-Chakrabarty has been an active ASH member since 2003 and is currently chair of the Committee on Government Affairs, co-chair of the Advocacy Leadership Institute, and served as an appointed member on the Guideline Oversight Committee. Her research has focused largely on leukemia, transplantation and imaging of marrow failure syndromes.
“Drs. Dunbar, Brown, Holter-Chakrabarty and Donald bring their unique perspectives and insights to ASH,” Mohandas Narla, DSc, distinguished scientist at New York Blood Center Enterprises and current ASH president, said in the release. “They are experts in their field, and their strong leadership will guide and shape the society in the coming years. With their forward-thinking counsel, ASH will continue to spearhead innovative education, groundbreaking research and transformative advocacy to drive meaningful change for patients with blood disorders worldwide.”
Read more about
Click Here to Manage Email Alerts